[1]罗 哲,刘平平,郭忠平.沙库巴曲缬沙坦钠片与恩格列净联合治疗慢性阻塞性肺疾病并慢性心力衰竭的效果评价[J].医学信息,2025,38(04):116-119.[doi:10.3969/j.issn.1006-1959.2025.04.020]
　LUO Zhe,LIU Pingping,GUO Zhongping.Effect Evaluation of Sacubitril Valsartan Sodium Tablets Combined with Empagliflozin in the Treatment of Chronic Obstructive Pulmonary Disease and Chronic Heart Failure[J].Journal of Medical Information,2025,38(04):116-119.[doi:10.3969/j.issn.1006-1959.2025.04.020]
点击复制

沙库巴曲缬沙坦钠片与恩格列净联合治疗慢性阻塞性肺疾病并慢性心力衰竭的效果评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年04期
页码:
116-119
栏目:
论著
出版日期:
2025-02-15

文章信息/Info

Title:
Effect Evaluation of Sacubitril Valsartan Sodium Tablets Combined with Empagliflozin in the Treatment of Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
文章编号:
1006-1959（2025）04-0116-04
作者:
罗 哲; 刘平平; 郭忠平
信丰县人民医院心血管内科，江西 信丰 341600
Author(s):
LUO Zhe;  LIU Pingping;  GUO Zhongping
Department of Cardiology, Xinfeng County People’s Hospital, Xinfeng 341600, Jiangxi, China
关键词:
慢性阻塞性肺疾病; 慢性心力衰竭; 沙库巴曲缬沙坦钠片; 恩格列净; 心肺功能
Keywords:
Chronic obstructive pulmonary disease;  Chronic heart failure;  Sacubitril valsartan sodium tablets;  Engliflozin;  Cardiopulmonary function
分类号:
R972
DOI:
10.3969/j.issn.1006-1959.2025.04.020
文献标志码:
A
摘要:
目的 研究沙库巴曲缬沙坦钠片（LCZ696）与恩格列净联合治疗慢性阻塞性肺疾病（COPD）并慢性心力衰竭（CHF）的临床效果。方法 选取2023年1月-9月信丰县人民医院心血管内科收治的68例COPD并CHF患者按照随机数字表法分为对照组34例，观察组34例，两组均给予基础治疗，在此基础上，对照组采用LCZ696治疗，观察组则选择LCZ696联合恩格列净治疗。比较两组临床治疗效果、心肺功能指标[左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、第1秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）]及不良反应。结果 观察组总有效率为97.06%，高于对照组的82.35%（P＜0.05）。两组治疗后LVEF、FEV1、FEV1/FVC升高，LVEDD降低，与对照组相比，观察组LVEF、FEV1、FEV1/FVC更高，LVEDD更低（P＜0.05）。观察组不良反应发生率（8.82%）与对照组（5.88%）相比，差异无统计学意义（P＞0.05）。结论 LCZ696联合恩格列净治疗COPD并CHF效果肯定，可提高其临床治疗效率，改善患者心肺功能，且用药安全性良好。
Abstract:
Objective To study the clinical effect of sacubitril valsartan sodium tablets (LCZ696) combined with empagliflozin in the treatment of chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). Methods A total of 68 patients with COPD and CHF admitted to the Department of Cardiology, Xinfeng County People’s Hospital from January to September 2023 were divided into control group (34 patients) and observation group (34 patients) by using the random number table method. Both groups were given basic treatment. On this basis, the control group was treated with LCZ696, while the observation group was treated with LCZ696 combined with empagliflozin. The clinical efficacy, cardiopulmonary function indexes [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), forced expiratory volume in one second (FEV1), FEV1/forced vital capacity (FVC)] and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 97.06%, which was higher than 82.35% of the control group (P<0.05). After treatment, LVEF, FEV1, FEV1/FVC increased and LVEDD decreased in the two groups. Compared with the control group, LVEF, FEV1, FEV1/FVC were higher and LVEDD was lower in the observation group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (8.82%) and the control group (5.88%) (P>0.05). Conclusion LCZ696 combined with empagliflozin is effective in the treatment of COPD and CHF, which can improve the clinical treatment efficiency, improve the cardiopulmonary function of patients, and the safety of medication is good.

参考文献/References:

[1]甘红英.无创呼吸机治疗高龄慢性阻塞性肺疾病合并左心衰竭的临床疗效[J].中西医结合心脑血管病杂志,2018,16(10):1401-1402.[2]李双双,李超,来静,等.慢阻肺伴左心衰竭临床特征与影响因素分析[J].现代生物医学进展,2022,22(22):4326-4330,4370.[3]何莹,程媛媛,刘玉杰.美托洛尔对老年CHF合并COPD患者疾病进程和心肺功能的影响[J].海南医学,2021,32(23):3015-3018.[4]杨凯,任斐,江成功,等.沙库巴曲缬沙坦对慢性心力衰竭患者室性心律失常及心率变异性的影响[J].江苏医药,2022,48(9):905-908.[5]郝正阳,张彦周.慢性射血分数降低性心力衰竭合并糖耐量受损患者服用恩格列净的有效性和安全性[J].中国循证心血管医学杂志,2022,14(9):1100-1103.[6]尹桂芝,陆益,宗小娟,等.沙库巴曲缬沙坦钠治疗慢性心衰合并肾功能不全的效果[J].中国临床医学,2022,29(4):615-620.[7]杨昌林.沙库巴曲缬沙坦钠片治疗高龄慢性心力衰竭效果观察[J].人民军医,2019,62(9):847-849,855.[8]姜阳,董鹏,刘芳,等.沙库巴曲缬沙坦治疗慢性心力衰竭的有效性及安全性研究[J].中国分子心脏病学杂志,2020,20(2):3297-3300.[9]王文科,徐金枝,苏振丽,等.恩格列净联合芪苈强心胶囊对慢性充血性心力衰竭患者的临床疗效及安全性观察[J].贵州医药,2021,45(12):1931-1932.[10]周桂全,王颖,潘文旭,等.恩格列净通过调控成纤维细胞分化改善心脏重构的研究[J].重庆医学,2022,51(23):3966-3970,3975.[11]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[12]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[13]陈兆彦,孙强.沙库巴曲缬沙坦对顽固性心力衰竭患者康复治疗及左心室射血分数的影响[J].中华老年心脑血管病杂志,2021,23(4):379-382.[14]高建全,呼玲玲.无创机械通气治疗慢性阻塞性肺疾病合并左心衰竭的临床疗效[J].山西医药杂志,2020,49(21):2947-2949.[15]吕超,覃雅婷,卢力,等.沙库巴曲缬沙坦联合辅酶Q10治疗慢性心力衰竭52例[J].医药导报,2020,39(11):1511-1515.[16]郑冠群,盛晓东.沙库巴曲/缬沙坦治疗慢性心力衰竭的效果及对左心重构与超敏肌钙蛋白T水平的影响[J].中国循证心血管医学杂志,2021,13(10):1210-1213.[17]Macfadyen J.Empagloflozin Use in a Community Heart Failure Clinic—Renal Safety and Tolerance[J].Canadian Journal of Diabetes,2018,42(5):45.[18]万一鸣,桑海强,董建增,等.恩格列净治疗射血分数降低的心力衰竭的药物经济学评价[J].中国药房,2022,33(1):74-78.[19]Banerjee M,Pal R,Nair K,et al.SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis[J].Indian Heart Journal,2023,75(2):122-127.[20]闫春秀,吕聪敏.恩格列净与利格列汀对2型糖尿病合并心力衰竭患者的临床疗效[J].中国新药与临床杂志,2022,41(4):234-237.[21]陆露,沈心逸,冯升.沙库巴曲缬沙坦钠治疗慢性心力衰竭的有效性及安全性评价[J].山西医药杂志,2020,49(9):1122-1125.[22]王建花,赵亨廷,孙玉霞,等.恩格列净对慢性心力衰竭大鼠肾脏功能和肾脏AQP2表达的影响及机制研究[J].联勤军事医学,2023,37(1):11-16.[23]杨莉,张旭东,詹小青,等.糖-钠协同转运蛋白2抑制剂对心力衰竭合并糖尿病小鼠治疗效果及左心室重构影响的实验研究[J].现代生物医学进展,2021,21(16):3032-3037.[24]Younes AM,Salem M,Maraey A,et al.Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis[J].International Journal of Cardiology,2022,366:51-56.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(04):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]贺明清,刘孝娅.环磷腺苷葡胺治疗慢性心力衰竭临床疗效观察[J].医学信息,2018,31(10):135.[doi:10.3969/j.issn.1006-1959.2018.10.045]
　HE Ming-qing,LIU Xiao-ya.Clinical Efficacy of Cyclic Adenosine Glucosamine in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2018,31(04):135.[doi:10.3969/j.issn.1006-1959.2018.10.045]
[8]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[9]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(04):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 1900-01-01